State of Tennessee Department of Treasury Lowers Position in IQVIA Holdings Inc. (NYSE:IQV)

State of Tennessee Department of Treasury lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 84,749 shares of the medical research company's stock after selling 3,421 shares during the quarter. State of Tennessee Department of Treasury's holdings in IQVIA were worth $16,654,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in IQV. Synergy Asset Management LLC purchased a new stake in IQVIA during the 4th quarter valued at $33,000. GKV Capital Management Co. Inc. bought a new position in IQVIA during the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. increased its stake in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares during the period. Finally, Versant Capital Management Inc lifted its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after acquiring an additional 93 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. UBS Group reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and reduced their target price for the stock from $260.00 to $160.00 in a report on Friday. Finally, Robert W. Baird dropped their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Seven equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $237.62.

IQVIA Stock Performance

IQV traded down $0.30 during midday trading on Friday, hitting $150.38. 1,333,062 shares of the company traded hands, compared to its average volume of 1,420,529. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company's 50-day moving average is $171.60 and its 200 day moving average is $194.05. The firm has a market capitalization of $26.51 billion, a PE ratio of 20.05, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.